The historical rank and industry rank for Klotho Neurosciences's PB Ratio or its related term are showing as below:
KLTO'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 3.72
Current: 3.72
During the past 4 years, Klotho Neurosciences's highest PB Ratio was 3.72. The lowest was 0.00. And the median was 0.00.
KLTO's PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 2.8
vs KLTO: 3.72
During the past 12 months, Klotho Neurosciences's average Book Value Per Share Growth Rate was 15.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -13.50% per year.
During the past 4 years, the highest 3-Year average Book Value Per Share Growth Rate of Klotho Neurosciences was -13.50% per year. The lowest was -13.50% per year. And the median was -13.50% per year.
Back to Basics: PB Ratio
Klotho Neurosciences (NAS:KLTO) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Klotho Neurosciences PB Ratio Related Terms
Klotho Neurosciences PB Ratio Historical Data
* Premium members only.
The historical data trend for Klotho Neurosciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Klotho Neurosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Klotho Neurosciences PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Klotho Neurosciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Klotho Neurosciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Klotho Neurosciences (KLTO) has a PB Ratio of 3.72 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Klotho Neurosciences and its competitors.
Is Klotho Neurosciences' PB Ratio too high?
Klotho Neurosciences' current PB Ratio is 3.72. The Biotechnology industry median PB Ratio is 2.80. Klotho Neurosciences' value of 3.72 is 32.9% above this industry median. Overall, Klotho Neurosciences has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Klotho Neurosciences' PB Ratio compare to KTTA and JUNS?
Klotho Neurosciences' PB Ratio of 3.72 can be compared against companies in the Biotechnology industry. The industry median PB Ratio is 2.80. Klotho Neurosciences' value of 3.72 is 32.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Klotho Neurosciences's current PB Ratio of 3.72 is 32.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Klotho Neurosciences and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Klotho Neurosciences's current PB Ratio is 3.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Klotho Neurosciences stock overvalued right now?
Klotho Neurosciences (KLTO) has a current PB Ratio of 3.72. The current PB Ratio is 3.72 and 32.9% above the Biotechnology industry median of 2.80. Klotho Neurosciences' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Klotho Neurosciences (KLTO), the current PB Ratio is 3.72 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.
22GF Score
Get the complete analysis for KLTO
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KLTO has been successfully added to your 
